We propose a hierarchical latent Dirichlet allocation model (HiLDA) for characterizing somatic mutation data in cancer. The method allows us to infer mutational patterns and their relative frequencies in a set of tumor mutational catalogs and to compare the estimated frequencies between tumor sets. We apply our method to somatic mutations in colon cancer with mutations classified by the time of occurrence, before or after tumor initiation. Applying the methods to 16 colon cancers, we found significant associations between the relative frequencies of mutational patterns and the time of occurrence of mutations. Our novel method provides higher statistical power for detecting differences in mutational signatures. 13 14 15 16 17 18 19 29 cancer subtypes. Moreover, by classifying mutations by their time of occurrence, before or after tumor 30 initiation, we can investigate whether new mutational processes occur during tumor growth. 31 Previous studies interested in comparing mutational exposure estimates between different groups of 32 tumor catalogs conducted a post hoc analysis. The analysis proceeded in two stages. First, they performed 33 one of the several different approaches for mathematically extracting the latent mutational signatures 34 and their exposures from the mutational catalogs (see Baez-Ortega and Gori (2017) for a review of such 35 methods). Later, they conducted an independent test of association between the point estimates of the 36 mutational exposures and external covariates. Examples of 1covariates included cancer subtype, or patient 37 history of alcohol or tobacco use. A common choice for the second stage test is a Wilcoxon rank-sum test 38 However, the variation of the exposure estimates is affected by two factors, the number of mutations in 41 the tumor and the variation in exposure frequency in the patient population. The former, the number of 42 mutations in the tumor, affects the accuracy of the exposure estimates. The application of the Wilcoxon 43 rank-sum test on the exposure estimates does not take into consideration their accuracy, which can lead to 44 loss of efficiency and test power. We address this by introducing a unified parametric model for testing 45 variation of mutational exposures between groups of mutational catalogs, where the exposure frequencies 46 48 latent Dirichlet allocation (LDA) model from Shiraishi et al. (2015). Shiraishi's model, like the majority 49 of deconvolution approaches, focuses on signatures for single-nucleotide substitutions, characterizing the 50 mutation types by context, using local features in the genome such as the pattern of flanking bases and 51 possibly the transcription strand. For both model parsimony and interpretation, we choose to extend their 52 LDA model. First, it requires fewer parameters than competing methods, giving it higher power to detect 53 patterns 5 bases in length compared to other models that consider only 3-base contexts (Shiraishi et al., 54 2015). Second, signature visualization methods lead to easy interpretation; an example is the common 55 C>T substitution at CpG sites instead of the more complicated NpCpG patterns that appear when using 56 the trinucleotide context. Like the LDA model, HiLDA retains all the functionality for estimating both 57 the latent signatures and the latent mutational exposure of each signature for each tumor catalog. Our 58 newly-added hierarchical level allows HiLDA to simultaneously test whether those mean exposures differ 59 between different groups of catalogs while accounting for the uncertainty in the exposure estimates.
INTRODUCTION 20
A variety of mutational processes occur over the lifetime of an individual, and thereby uniquely contribute 21 to the catalog of somatic mutations observed in a tumor. Some processes leave a molecular signature: a 22 specific base substitution occurring within a particular pattern of neighboring bases. A variety of methods 23 exist to discover mutational signatures from the catalog of all somatic mutations in a set of tumors, 24 estimating the latent mutational signatures as well as the latent exposures (i.e., fraction of mutations) each 25 signature contributes to the total catalog. The first large study of mutational signatures in cancer identified 26 variation in mutational signatures and mutational exposures across 21 different cancer types (Alexandrov 27 et al., 2013) . To better understand the sources of variation in the mutational exposures across cancers, our 28 interest is in statistical methods used to characterize these latent mutational exposures across different are modeled using a Dirichlet distribution.
We propose a hierarchical latent Dirichlet allocation model (HiLDA) that adds an additional level to the
For full details see See Text S1. and Fig. S2 ..
99

Testing for Differences in Signature Exposures
100
To characterize the signature contributions for different sets of tumor catalogs, we wish to conduct a 101 hypothesis test that there is no difference in mean exposures versus the alternative that the mean exposure 102 of at least one signature differs between the two groups, i.e. H 0 : µ µ µ (1) = µ µ µ (2) vs. H 1 : at least one 103 µ k
(1) = µ k (2) . We propose both local and global tests, implemented in a Bayesian framework. The former 104 provides signature-level evaluations to determine where the differences in mean mutational exposures 105 occur, while the latter provides an overall conclusion about any difference in mean mutational exposures.
106
The details of our implementation are given in our Just Another Gibbs Sampler (JAGS) scripts and Source 107 code is freely available in Github at https://github.com/USCbiostats/HiLDA (Plummer et al., 2003) .
108
A local test to identify signatures with different exposures 109 We propose a signature-level (local) hypothesis test to allow us to infer which signature(s) contribute a different mean exposure to the mutational catalogs across tumor sets, i.e., µ k (1) = µ k (2) . To measure the difference between mean signature exposure vectors, we implement HiLDA by specifying two Dirichlet distributions, Dir(α α α (1) ) and Dir(α α α (2) ), as priors for the distribution of mutational exposuresi of each group (Spiegelhalter et al., 2003) . Using this formulation, the difference between the two groups of the mean exposure of signature k is calculated as,
For all parameters, α
k 's and α
k 's, we use independent, non-informative gamma distribution priors with a rate of 0.001 and shape of 0.001; this results in a mean of 1 and variance of 1000. So,
We estimate parameters via Markov chain Monte Carlo (MCMC) using two chains (Carlin and Chib, 110 1995). We assess convergence of the two MCMC chains using the potential scale reduction factor (Rhat) 111 in Gelman et al. (1992) , which is required to be less than or equal to 1.05 for all parameters in order to 112 conclude that the MCMC run has converged. After obtaining the posterior distribution of the differences 113 (i.e., of ∆ k ), there are two possible approaches to performing inference. We can: 1) use the Wald test to 114 compute the P-value using the means and standard errors of the posterior distribution for ∆ k ; 2) determine 115 whether the 95% credible interval of the posterior distribution for ∆ k contains zero.
116
A global test using the Bayes factor 117 We also propose a global test to provide an overall conclusion on whether the mean exposures differ between groups of catalogs. It uses the Bayes factor, the ratio of posterior to prior odds in favor of the alternative (H 1 : at least one µ (1) k = µ
(2) k , k = 1, ..., K) compared to the null (H 0 : µ µ µ (1) = µ µ µ (2) ), to indicate the strength of evidence that they do differ, without explicit details on how they differ. Thus, we can calculate the Bayes factor as: Observed mutation characteristic vector, (x i, j,1 , . . . , x i, j,L ), for the jth mutation from the ith mutational catalog (indexed by x i, j,l ) z i, j
Index of the latent assignment for X X X i, j , z i, j ∈ {1, . . . , K}i,k Probability vector of signature k exposure in mutational catalog i, 
, the difference in the mean exposure of signature k in group 1 and 2. b 95% credible interval from the posterior distribution. 
, the difference in the mean exposure of signature k in group 1 and 2. b 95% credible interval from the posterior distribution. Table 4 . The false positive rates (n = 1,000) and true positive rates (n = 200) of both the two-stage method and HiLDA when applied to the simulated data.
in human cancer. bioRxiv, page 322859.
